Infinity gets FDA fast track designation for IPI-549, Opdivo combo in urothelial cancer
Infinity Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IPI-549 in combination with nivolumab (Opdivo) for the…
Read More...
Read More...
